TYK2

Across TCGA pan-cancer cohorts, TYK2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of TYK2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TYK2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TYK2 is over-expressed in tumor.

HNSC, KIRC, and COAD are the cancer types where TYK2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TYK2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.071	<.001	12	view →
KIRC	Male	IV	+0.949	<.001	12	view →
COAD	Male	III,IV	+0.713	<.001	10	view →
LIHC	Female	II,III,IV	+1.228	<.001	9	view →
BLCA	All	All	+0.741	<.001	9	view →
KIRP	Female	All	+0.644	<.001	9	view →
STAD	Male	II,III,IV	+1.220	<.001	8	view →
ESCA	All	All	+0.862	<.001	5	view →
UCEC	All	All	+0.455	.008	4	view →
BRCA	All	II,III,IV	+0.208	.008	4	view →
CHOL	Male	All	+1.928	<.001	3	view →
READ	All	All	+0.623	.004	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

TYK2–HNSC

Open the HNSC breakdown →